Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Study With Controlled Human Malaria Infection (CHMI) to Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

Next Previous
X
Search
Trial Profile

A Phase I Dose Escalation Study With Controlled Human Malaria Infection (CHMI) to Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLPM 01 (Primary)
  • Indications Malaria
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors VLP Therapeutics

    • Most Recent Events

    • 06 Apr 2021 Status changed from recruiting to completed.
    • 07 Mar 2019 Status changed from planning to recruiting.
    • 04 Feb 2019 According to a VLP Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for this trial. Enrolment in this trial is expected to start in February 2019. This trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, Maryland.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top